Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01856543 · ClinicalTrials.gov registry record · Phase 3
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
A Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 143
- Enrollment target
NCT01856543: Completed Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01856543 is a Phase 3 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 143 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01856543, a Phase 3 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 143 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if the effect of mometasone furoate is any different from Eucerin in decreasing the severity of redness of the skin during irradiation, preventing the skin from peeling, or reducing the amount of irritation the patient reports during treatment.
Interventions
- OTHER Eucerin
- OTHER Mometasone Furoate 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2013-05 |
| Est. Completion | 2017-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01856543
The ClinicalTrials.gov registry entry for NCT01856543 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Eucerin is the first listed.
NCT01856543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01856543 about?
NCT01856543 is a clinical study titled "Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation". The purpose of this study is to find out if the effect of mometasone furoate is any different from Eucerin in decreasing the severity of redness of the skin during irradiation, preventing the skin from peeling, or reducing the amount of irritation the patient reports during treatment.
What is the current status of trial NCT01856543?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 143 participants. The study started on 2013-05. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01856543?
The interventions under investigation include: Eucerin (OTHER), Mometasone Furoate 0.1% (OTHER).
Who is sponsoring clinical trial NCT01856543?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.